ReviewCurrent gastroenterology reports2016
Management of Difficult Cases of Autoimmune Hepatitis.
Review in Current gastroenterology reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 17 citations in OpenAlex.
- Refractory autoimmune hepatitis in children: Considerations for assessment and management.World journal of hepatology · 2025Review
- Autoimmune Hepatitis and Drug-Induced Liver Injury in Japan.Journal of clinical medicine · 2025Review
- IL-15-producing splenic B cells play pathogenic roles in the development of autoimmune hepatitis.JHEP reports : innovation in hepatology · 2023Article
- Natural history and management of refractory autoimmune hepatitis.Clinical liver disease · 2022Review
- Article
- Autoimmune Hepatitis: Clinical Characteristics and Predictors of Biochemical Response to Treatment.Journal of translational internal medicine · 2020Article
- Novel HLA Class I Alleles Outside the Extended DR3 Haplotype Are Protective against Autoimmune Hepatitis.Clinical and translational gastroenterology · 2019Article
- Extrahepatic Autoimmune Diseases are Prevalent in Autoimmune Hepatitis Patients and Their First-Degree Relatives: Survey Study.Interactive journal of medical research · 2018Article
- The Saudi association for the study of liver diseases and transplantation clinical practice guidelines for management of autoimmune hepatitis.Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association · 2018Article
- Potential triggering factors of acute liver failure as a first manifestation of autoimmune hepatitis-a single center experience of 52 adult patients.World journal of gastroenterology · 2018Article
- Endogenous n-3 Polyunsaturated Fatty Acids Attenuate T Cell-Mediated Hepatitis via Autophagy Activation.Frontiers in immunology · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
Abstract
Autoimmune hepatitis (AIH) is a complex autoimmune disease characterized by immune-mediated destruction of hepatic parenchyma which can result in cirrhosis, liver failure, and death. Current American Association for the Study of Liver Diseases (AASLD) and European Association for the Study of Liver (EASL) guidelines recommend corticosteroids alone or in combination with azathioprine as first-line treatment strategies. However, a significant proportion of patients may not be able to tolerate or achieve complete biochemical response with these options. In this article, we discuss approaches to these patients and other challenging AIH patient groups such as the asymptomatic, pregnant, elderly, and liver transplant recipients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.